Luye Pharma Group Ltd. (HKG:2186)
Hong Kong · Delayed Price · Currency is HKD 3.410
+0.150 (4.60%)
Sep 30, 2025, 4:08 PM HKT
Luye Pharma Group Revenue
Luye Pharma Group had revenue of 3.18B CNY in the half year ending June 30, 2025, with 9.54% growth. This brings the company's revenue in the last twelve months to 6.17B, down -2.31% year-over-year. In the year 2024, Luye Pharma Group had annual revenue of 6.06B, down -1.33%.
Revenue (ttm)
6.17B CNY
Revenue Growth
-2.31%
P/S Ratio
2.02
Revenue / Employee
1.20M CNY
Employees
5,150
Market Cap
13.62B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.06B | -81.64M | -1.33% |
| Dec 31, 2023 | 6.14B | 161.42M | 2.70% |
| Dec 31, 2022 | 5.98B | 781.43M | 15.03% |
| Dec 31, 2021 | 5.20B | -339.42M | -6.13% |
| Dec 31, 2020 | 5.54B | -818.21M | -12.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 35.81B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| WuXi Biologics | 21.98B |
| Innovent Biologics | 12.52B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |
Luye Pharma Group News
- 1 year ago - RRJ Buys $150 Million Luye Bonds, First China Deal Since 2019 - BNN Bloomberg